Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis.

@article{Suzuki2010TacrolimusAC,
  title={Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis.},
  author={Katsunori Suzuki and Kazuyoshi Saito and Shizuyo Tsujimura and Shingo Nakayamada and Kunihiro Yamaoka and Norifumi Sawamukai and Shigeru Iwata and Masao Nawata and Kazuhisa Nakano and Yoshiya Tanaka},
  journal={The Journal of rheumatology},
  year={2010},
  volume={37 3},
  pages={512-20}
}
OBJECTIVE Tacrolimus, a calcineurin inhibitor, is used for treatment of rheumatoid arthritis (RA). It also inhibits functions of P-glycoprotein, which is involved in drug resistance. We examined the mechanisms of early response to 2-week tacrolimus treatment in patients with RA. METHODS One hundred thirteen patients with refractory RA despite at least 3… CONTINUE READING